Related Experiment Video
Updated: Jul 1, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
[Study on clinicopathological correlations between metabolic syndrome and colorectal carcinoma]
Zhan-Long Shen1, Shan Wang, Ying-Jiang Ye
1Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing 100044, China. shenlong1977@163.com
Objective:
To explore the clinicopathological relationship between metabolic syndrome (MS) and colorectal cancer.
Methods:
The clinical data of 507 cases of colorectal cancer (colorectal cancer group) and 277 cases of nontumorous diseases (control group) treated from January 2002 to March 2007 were collected to set up the database. The patients with colorectal carcinoma were divided into two groups according to the presence of MS: MS group and non-MS group. Some clinicopathological factors were analyzed and compared between the two groups, such as age, gender, blood pressure, tumor family history, hypertension and diabetes mellitus history, body mass index (BMI), glucose (GLU), triglyceride (TG), cholesterol (CHO), high density lipoprotein (HDL), lactate dehydrogenase (LDH), uric acid (UA), carcinoembryonic antigen (CEA) , CA19-9, the tumor position, pathological stage, and liver metastasis.
Results:
The morbidity rate of metabolic syndrome in the colorectal cancer group was significantly higher than that in control group. The rate of liver metastasis and tumor recurrence in the MS group was significantly higher than that in the non-MS group.
Conclusion:
To understand the relationship between MS and colorectal cancer is important for reducing the incidence of MS and colorectal cancer and the recurrence of the tumor and live metastasis.
